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Abstract—Pulsatile blood pressure (BP) confers cardiovascular risk. Whether associations of cardiovascular end points are 
tighter for central systolic BP (cSBP) than peripheral systolic BP (pSBP) or central pulse pressure (cPP) than peripheral 
pulse pressure (pPP) is uncertain. Among 5608 participants (54.1% women; mean age, 54.2 years) enrolled in nine 
studies, median follow-up was 4.1 years. cSBP and cPP, estimated tonometrically from the radial waveform, averaged 
123.7 and 42.5 mm Hg, and pSBP and pPP 134.1 and 53.9 mm Hg. The primary composite cardiovascular end point 
occurred in 255 participants (4.5%). Across fourths of the cPP distribution, rates increased exponentially (4.1, 5.0, 7.3, 
and 22.0 per 1000 person-years) with comparable estimates for cSBP, pSBP, and pPP. The multivariable-adjusted hazard 
ratios, expressing the risk per 1-SD increment in BP, were 1.50 (95% CI, 1.33–1.70) for cSBP, 1.36 (95% CI, 1.19–1.54) 
for cPP, 1.49 (95% CI, 1.33–1.67) for pSBP, and 1.34 (95% CI, 1.19–1.51) for pPP (P<0.001). Further adjustment of 
cSBP and cPP, respectively, for pSBP and pPP, and vice versa, removed the significance of all hazard ratios. Adding 
cSBP, cPP, pSBP, pPP to a base model including covariables increased the model fit (P<0.001) with generalized R2 
increments ranging from 0.37% to 0.74% but adding a second BP to a model including already one did not. Analyses of 
the secondary end points, including total mortality (204 deaths), coronary end points (109) and strokes (89), and various 
sensitivity analyses produced consistent results. In conclusion, associations of the primary and secondary end points with 
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Blood pressure (BP) is the main modifiable cardiovas-cular risk factor.1 Diastolic and mean arterial BP (MAP), 
the steady BP components, drive blood flow and are similar 
throughout the arterial tree from the ascending aorta up to the 
small arterioles, running through vital organs.2 Systolic BP and 
pulse pressure (PP), the difference between systolic and dias-
tolic BP oscillate around MAP, make up the pulsatile compo-
nent of BP. Over half a century of research established systolic 
BP and PP as cardiovascular risk factor, in particular, in older 
adults.2 Placebo-controlled randomized trials in patients with 
isolated systolic hypertension proved that lowering systolic 
BP reduced overall cardiovascular risk by over 30%.3 Over 
the human lifespan, PP becomes wider because aging and 
age-related morbid conditions, such as hypertension, diabetes 
mellitus, or chronic kidney disease degrade the elastic proper-
ties of large arteries.2 Widening of PP at any age is predomi-
nantly associated with a larger forward pressure wave,4 thereby 
increasing the load on the left ventricle,5 causing target organ 
damage,6 and ultimately cardiovascular complications.6
Central systolic BP and central PP are lower than their 
peripheral counterparts are.2 The perception that the pulsa-
tile BP component confers risk and the anatomic proximity 
of the aorta to the heart, brain, and kidney, gave rise to the 
hypothesis that cardiovascular complications must be more 
closely associated with central than peripheral systolic BP 
and PP.7 However, the evidence supporting a tighter associa-
tion of cardiovascular end points with central than peripheral 
BP, remains controversial.7 To address this knowledge gap, we 
constructed the IDCARS (International Database of Central 
Arterial Properties for Risk Stratification), in which data from 
nine prospective population studies were harmonized and ana-
lyzed. In this article, we compared associations of fatal and 
nonfatal cardiovascular end points with central and peripheral 
systolic BP and PP.
Methods
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.
Study Participants
All population studies included in IDCARS received ethical ap-
proval in their country of origin and adhered to the principles of 
the Declaration of Helsinki. Participants provided written informed 
consent. The anonymized IDCARS database was constructed at the 
Studies Coordinating Centre in Leuven, Belgium. IDCARS cohorts 
qualified for inclusion in the present analysis, if peripheral and cen-
tral BP and cardiovascular risk factors had been measured at base-
line, and if follow-up included both fatal and nonfatal outcomes. The 
Data Supplement available online provide detailed information on 
the population sampling methods, timelines, and countries of recruit-
ment (Table S1 in the Data Supplement). Initial enrollment took place 
from 1985 until 2015. For the present analysis, baseline refers to the 
first measurement of central and peripheral BP along with cardiovas-
cular risk factors (October 2000 until February 2016). Across studies, 
the last follow-up took place from October 2012 to December 2018 
(Table S1). References describing the nine cohorts are available in 
Table S2 and References S1 to S23 in the Data Supplement.
BP Measurement
Peripheral BP was measured immediately before the hemodynamic 
assessment after participants had rested for at least 5 minutes in the 
supine position, using standard mercury sphygmomanometers or vali-
dated oscillometric devices (Table S3). Peripheral BP was the average 
or the last of 2 consecutive readings. MAP was peripheral diastolic 
BP plus one-third of PP. Estimates of central BP were calibrated on 
peripheral systolic and diastolic BP. Experienced observers recorded 
the radial arterial waveform at the dominant arm during an 8-second 
period by applanation tonometry. They used a high-fidelity SPC-301 
micromanometer (Millar Instruments Inc., Houston, TX), interfaced 
with a SphygmoCor CvMS device and a laptop computer running 
SphygmoCor software. Recordings were discarded if the systolic 
or diastolic variability of consecutive waveforms exceeded 5% or if 
the amplitude of the pulse wave signal was below 80 mV, or if the 
operator index was <70%. From the radial signal, the SphygmoCor 
software reconstructs the aortic pulse wave by means of a validated 
generalized transfer function.8 The software returns systolic, dias-
tolic, MAP, and PP in the ascending aorta.
Ascertainment of End Points
We ascertained vital status and the incidence of fatal and nonfatal 
end points from the appropriate sources in each country. Prespecified 
end points were coded according to the International Classification of 
Diseases (Table S4). The primary end point was a composite cardio-
vascular outcome consisting of cardiovascular mortality and nonfatal 
end points, including myocardial infarction, heart failure, stroke, and 
coronary revascularization. Secondary end points included total mor-
tality, fatal and nonfatal coronary end points, and fatal and nonfatal 
stroke, not including transient ischemic attack. All end points were 
validated against hospital files or medical records held by primary 
care physicians or specialists. In all outcome analyses, only the first 
event within each category was considered. No participant was lost 
to follow-up.
Statistical Analysis
For database management and statistical analysis, we used SAS soft-
ware, version 9.4, maintenance level 5. For between-group compar-
ison of means and proportions, we applied the large-sample Z test 
and the Fisher exact test, respectively. After stratification for cohort 
and sex, we interpolated missing values of body mass index, serum 
creatinine, and blood glucose from the regression slopes on age. In 
participants with unknown status of smoking or drinking, we set the 
indicator (dummy) variable to the cohort- and sex-specific mean of 
the codes (0, 1). For the cohort recruited in Buenos Aires, Argentina, 
we extrapolated alcohol consumption from national statistics strati-
fied by sex and age.9 To compute 95% CIs of rates, we applied the for-
mula as R R T± ×1.96 ( / ),  where R and T are the rate and the number 
of individuals used to compute the rate.
In multivariable-adjusted Cox regression, we accounted for co-
hort (random effect), sex, and baseline characteristics including age, 
body mass index, smoking and drinking status, the ratio of total-to-
HDL (high-density lipoprotein) serum cholesterol, the estimated 
glomerular filtration rate (Chronic Kidney Disease-Epidemiology 
Collaboration equation), antihypertensive drug intake, history of 
cardiovascular disease, and diabetes mellitus. To adjust for cohort, 
we pooled participants recruited in the framework of the European 
Project on Genes in Hypertension (Kraków, Pilsen, and Padova; 
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Table S1). We checked the proportional hazards assumption by the 
Kolmogorov-type supremum test and by testing the interaction be-
tween follow-up duration and the BP variables. In Cox models, in-
cluding 2 BP indexes, we uncorrelated the BP levels by regressing 
one index on the other and by using the residual of one BP index and 
the measured level of the other. The residual of one BP index is the 
part of this BP index, which is unrelated to its counterpart on which 
it was regressed.10,11 We constructed heat maps to visualize the con-
tribution of central and peripheral BP components to the associations 
with the end points.10,11 Improvement in the fit of nested Cox models 
was assessed by the log-likelihood ratio and the generalized R2 statis-
tic.12 Statistical significance was a 2-tailed α-level of ≤0.05.
Results
Baseline Characteristics of Participants
Of 6650 people qualifying for analysis, we excluded 1042 
because they were younger than 30 years without end points 
(n=954), peripheral PP was >130 mm Hg (n=10), central sys-
tolic BP was <70 mm Hg (n=1) or >230 mm Hg (n=1), central 
diastolic BP was >150 mm Hg (n=1) or <55 mm Hg (n=15), 
or because the pulse wave analysis was missing (n=60). This 
left 5608 participants for statistical analysis (Table 1). Missing 
values of body mass index (n=26), smoking (n=245), drink-
ing (n=1069), serum creatinine (n=192), and blood glucose 
(n=161) were interpolated. Mean age was 54.2 years (Table 1). 
The study population included 3034 women (54.1%), 2388 
(42.6%), 1823 (32.5%), and 1397 (24.9%) Europeans, Asians, 
and South Americans, 1179 smokers (21.0%), and 2818 
Table 1. Baseline Characteristics of Participants
Characteristic Statistic (n=5608)
Number (%) with characteristic
  Women 3034 (54.1)
  Europeans 2388 (42.6)
  Asians 1823 (32.5)
  South Americans 1397 (24.9)
  Current smoking* 1179 (21.0)
  Drinking alcohol* 2818 (50.3)
  Office hypertension† 2987 (53.3)
  On antihypertensive treatment* 1943 (34.7)
  Diabetes mellitus* 338 (6.03)
  History of cardiovascular disease* 792 (14.1)
  Renal dysfunction‡ 700 (12.5)
Mean (±SD) of characteristic
  Age, y 54.2±14.4
  Body mass index, kg/m2 25.8±4.8
Peripheral blood pressure, mm Hg†
  Systolic / diastolic, mm Hg 134.1±21.0/80.2±10.7
  Pulse pressure, mm Hg 53.9±16.3
Central blood pressure, mm Hg§
  Systolic / diastolic, mm Hg 123.7±21.2/81.2±10.9
  Pulse pressure, mm Hg 42.5±16.1
  Mean arterial blood pressure, mm Hg 99.3±13.8
Biochemistry‖
  Serum total cholesterol, mg/dL 195.4±38.9
  Serum HDL cholesterol, mg/dL 57.5±15.2
  Serum non-HDL cholesterol, mg/dL 137.9±39.2
  Total-to-HDL cholesterol ratio 3.60±1.11
  Serum creatinine, mg/dL 0.93±0.28
  Glomerular filtration rate, mL/(min·1.73 m2)‡ 82.5±19.6
  Blood glucose, mg/dL 90.7±19.2
HDL indicates high-density lipoprotein.
*Assessed by questionnaire at baseline. Current smoking was inhaling 
tobacco smoke on a daily basis. Drinking alcohol was the occasional or daily 
consumption of ethanol-containing beverages. Diabetes mellitus was use of 
antidiabetic drugs, fasting blood glucose of ≥126 mg/dL, random blood glucose 
of ≥200 mg/dL, a self-reported diagnosis, or diabetes mellitus documented in 
practice or hospital records.
†Peripheral blood pressure was measured immediately before the 
hemodynamic assessment after participants had rested in the supine position 
for ≥5 min with participants, using standard mercury sphygmomanometers or 
validated oscillometric devices. Hypertension was a blood pressure of ≥140 
mm Hg systolic or ≥90 mm Hg diastolic, or use of antihypertensive drugs.
‡The glomerular filtration rate was derived from serum creatinine using the 
Chronic Kidney Disease–Epidemiology Collaboration formula. Renal dysfunction 
was a glomerular filtration rate <60 mL/(min/1.73 m2).
§Central blood pressure was measured tonometrically (Table S3).
‖Measured at baseline by automated enzymatic methods in certified 
laboratories.
Table 2. Correlation Matrix Between Central and Peripheral BP
BP pSBP pDBP pPP cSBP cDBP cPP MAP
Correlations between measured peripheral and transfer-function derived 
central BP
  pSBP …       
  pDBP 0.64 …      
  pPP 0.87 0.17 …     
  cSBP 0.97 0.66 0.81 …    
  cDBP 0.65 0.99 0.18 0.67 …   
  cPP 0.84 0.20 0.95 0.86 0.20 …  
  MAP 0.89 0.89 0.56 0.91 0.90 0.59 …
Correlations of residual BP with measured peripheral and transfer-function 
derived central BP
  rpSBP 0.23 −0.08 0.34 0.00 −0.08 0.06 −0.04
  rpPP 0.15 −0.14 0.29 −0.07 −0.14 0.00 −0.10
  rcSBP 0.00 0.23 –0.15 0.23 0.24 0.14 0.25
  rcPP 0.10 0.21 0.00 0.32 0.21 0.29 0.28
MAP was peripheral diastolic BP plus one-third of pulse pressure (the 
difference between pSBP and pDBP). All correlation coefficients were significant 
(P<0.001) except for the correlation coefficients between the residuals and the 
measured or transfer-function derived values of the counterpart. BP indicates 
blood pressure; cSBP/cDBP, central systolic/diastolic BP; MAP, mean arterial 
BP; pPP/cPP, peripheral/central pulse pressure; pSBP/pDBP, peripheral systolic/
diastolic BP; rcSBP/rcPP, residuals derived by regressing cSBP/cPP on pSBP/
pPP; and rpSBP/rpPP, residuals of pSBP/pPP derived by regressing pSBP/pPP 
on cSBP/cPP.
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participants (50.3%) reporting alcohol consumption. Of 2987 
participants (53.3%) with office hypertension, 1943 (65.0%) 
were taking antihypertensive drug treatment. The prevalence 
of diabetes mellitus and a history of cardiovascular disease 
was 338 participants (6.03%) and 792 (14.1%), respectively. 
Table S5 and Table S6 list the baseline characteristics of par-
ticipants by fourths of the distribution of central and peripheral 
systolic BP. Risk factors, including male sex, the prevalence 
of hypertension, treated hypertension and renal dysfunction, 
age, body mass index, serum cholesterol, the total-to-HDL 
cholesterol ratio, and blood glucose consistently increased 
(P<0.001) across categories of central (Table S5) and periph-
eral (Table S6) systolic BP.
Peripheral and Central BP
Systolic/diastolic BP and PP averaged 134.1/80.2 mm Hg and 
53.9 mm Hg peripherally and 123.7/81.2 mm Hg and 42.5 
mm Hg centrally (Table 1). MAP averaged 99.3 mm Hg. On 
average, peripheral compared with central diastolic BP was 
1.04 mm Hg lower (95% CI, 1.02–1.06 mm Hg; P<0.001). 
Women had higher heart rate and central and peripheral PP, 
but lower peripheral systolic BP and lower central and periph-
eral diastolic BP than men had (Table S7). The central and 
peripheral BP levels were highly correlated (Table 2). Using 
the residual approach reduced the correlation coefficients be-
tween the corresponding peripheral and central BP indexes 
from 0.97 for systolic BP and 0.95 for PP to association sizes, 
which were infinitesimally small (Table 2). The residual BP 
levels were correlated to their original BP indexes with corre-
lation coefficients ranging from 0.23 to 0.29 and maintained 
their associations with sex (Table S7) and the continuous 
covariables, for which analyses were adjusted, that is, age, 
body mass index, the ratio of high to low-density cholesterol, 
and the estimated glomerular filtration rate (Table S8).
Absolute Risk Associated With Central and 
Peripheral BP
Median follow-up of 5608 participants amounted to 4.1 
years (fifth–95th percentile interval, 2.2–12.1 years). Across 
cohorts (Table S1), median follow-up ranged from 2.3 years 
(fifth–95th percentile interval, 1.4–3.1 years) to 14.0 years 
(fifth–95th percentile interval, 8.5–14.4 years). During 31610 
person-years of follow-up, the primary end point occurred in 
255 participants (4.5%); 109 (1.9%) and 89 (1.6%) partici-
pants experienced a coronary end point or stroke, and 204 
(3.6%) died. The corresponding rates expressed per 1000 
person-years (95% CI) were 8.2 (95% CI, 7.2–9.2), 3.5 
(95% CI, 2.8–4.1), 2.8 (95% CI, 2.2–3.4), and 6.5 (95% CI, 
5.6–7.3), respectively.
Across increasing fourths of the central systolic BP dis-
tribution (Table S9), the primary end point occurred in 14 
(1.0%), 36 (2.6%), 71 (5.1%), and 134 (9.6%) participants at 
Figure 1. Cumulative incidence of the primary 
end point by fourths of the distributions of 
central systolic blood pressure (cSBP) and 
peripheral systolic blood pressure (pSBP). 
Tabulated data are the number of participants 
at risk at 5-y intervals. P values for trend 
were derived by Cox proportional hazards 
regression. Estimates accounted for sex and 
age (A and B). There were no differences in 
hazard ratios between cSBP (A) and pSBP (B; 
P=0.86). Additional adjustment for pSBP (C) or 
cSBP (D) removed the significance.
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rates per 1000 person-years of 3.9, 5.1, 9.0, and 16.6, respec-
tively. Similarly, across fourths of the central PP distribution 
(Table S10), the primary end point occurred in 21 (1.5%), 
34 (2.4%), 54 (3.9%), and 146 (10.4%) participants at rates 
of 4.1, 5.0, 7.3, and 22.0 per 1000 person-years. These rate 
trends were consistent for the secondary end points across 
the categories of the central systolic BP and PP (Table S9 
and Table S10).
In all Cox models that follow, the proportional hazards 
assumption was met and the residual method, as described in 
the statistical methods, was applied if models included two 
BP components. The sex- and age-adjusted cumulative inci-
dence of the primary end point derived by Cox regression ran 
higher across increasing categories of central and peripheral 
systolic BP and PP. There were no differences in hazard ratios 
between central and peripheral BP components (P=0.86 for 
systolic BP and P=0.90 for PP, Figure 1A and 1B and Figure 
S1A and S1B). Additional adjustment of these BP compo-
nents for their counterpart weakened these associations to a 
nonsignificant level (Figure 1C and 1D and Figure S1C and 
S1D). Findings for the cumulative incidence of the coronary 
end points (Figure S2) and stroke (Figure S3) in relation to 
systolic BP and PP were confirmatory.
Relative Risk Associated With the Central and 
Peripheral Pulsatile BP Components
In analyses adjusted for cohort, sex, age, body mass index, 
smoking and drinking status, the total-to-HDL serum cho-
lesterol ratio, the estimated glomerular filtration rate, use of 
antihypertensive drugs, history of cardiovascular disease, and 
diabetes mellitus (Table 3), associations of the primary end 
point, total mortality, coronary end points, and stroke with 
systolic BP and PP were statistically significant (P≤0.037), 
irrespective of whether the pulsatile BP components were 
measured centrally or peripherally. The interaction terms be-
tween the pulsatile BP components and continent of recruit-
ment were not significant in any model (P≥0.18).
Further adjustment of central for peripheral pulsatile BP, 
and vice versa, removed the significance of the associations of 
the primary end point, total mortality, coronary end points and 
Table 3. Association of End Points With the Central and Peripheral Pulsatile BP Components
End Points (Number) 
BP Index*
Adjusted Additionally Adjusted for cSBP or cPP* Additionally Adjusted for pSBP or pPP*
HR (95% CI)† P Value HR (95% CI)†‡ P Value HR (95% CI)†‡ P Value
Primary (255)
  cSBP 1.50 (1.33–1.70) <0.001 …§ …§ 1.01 (0.53–1.93) 0.97
  cPP 1.36 (1.19–1.54) <0.001 …§ …§ 1.12 (0.67–1.89) 0.66
  pSBP 1.49 (1.33–1.67) <0.001 1.47 (0.79–2.74) 0.22 …§ …§
  pPP 1.34 (1.19–1.51) <0.001 1.20 (0.74–1.96) 0.47 …§ …§
Secondary
  Mortality (204)
  cSBP 1.16 (1.02–1.32) 0.025 …§ …§ 0.63 (0.31–1.31) 0.22
  cPP 1.18 (1.03–1.35) 0.017 …§ …§ 0.77 (0.42–1.38) 0.37
  pSBP 1.17 (1.04–1.33) 0.012 1.81 (0.90–3.65) 0.096 …§ …§
  pPP 1.19 (1.05–1.36) 0.008 1.53 (0.87–2.66) 0.14 …§ …§
Coronary (109)
  cSBP 1.29 (1.05–1.58) 0.016 …§ …§ 1.76 (0.64–4.84) 0.28
  cPP 1.30 (1.05–1.60) 0.014 …§ …§ 1.92 (0.85–4.33) 0.12
  pSBP 1.25 (1.03–1.53) 0.028 0.74 (0.28–1.96) 0.47 …§ …§
  pPP 1.23 (1.01–1.50) 0.037 0.68 (0.31–1.47) 0.33 …§ …§
Stroke (89)
  cSBP 1.65 (1.37–1.99) <0.001 …§ …§ 0.96 (0.32–2.88) 0.95
  cPP 1.46 (1.19–1.79) 0.003 …§ …§ 1.12 (0.46–2.70) 0.81
  pSBP 1.64 (1.37–1.96) <0.001 1.70 (0.59–4.89) 0.33 …§ …§
  pPP 1.43 (1.18–1.74) <0.001 1.30 (0.56–2.99) 0.81 …§ …§
BP indicates blood pressure; cPP, central pulse pressure; cSBP, central systolic BP; HDL, high-density lipoprotein; HR, hazard ratio; pPP, 
peripheral pulse pressure; and pSBP, peripheral systolic BP.
*pSBP/pPP, peripheral systolic blood pressure/pulse pressure; cSBP/cPP, central systolic blood pressure/pulse pressure.
†All HRs, given with 95% CI, expressed the relative risk associated with a 1-SD increment in BP and accounted for cohort, sex, age, body mass 
index, smoking and drinking, total-to-HDL serum cholesterol ratio, the estimated glomerular filtration rate, antihypertensive drug intake, history of 
cardiovascular disease, and diabetes mellitus.
‡HR were for the residual of the BP index.
§Not applicable.
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stroke with both pulsatile BP components (Table 3). The log-
likelihood ratios (Table 4) confirmed that adding a single pul-
satile BP component to a base model including all covariables 
increased model fit (P<0.001) with an increment in the gen-
eralized R2 statistic ranging from 0.37% to 0.74%. However, 
adding a second pulsatile BP index to a model including al-
ready one pulsatile BP component along with covariables did 
not. Heat maps associating the primary end point with central 
and peripheral systolic BP or with central and peripheral PP 
(Figure 2) provided a graphical confirmation of these findings. 
Heat maps relating the secondary end points to central and 
peripheral systolic BP (Figure S4) or to central and peripheral 
PP (Figure S5) were confirmatory.
Sensitivity Analysis
Hazard ratios relating to the primary end point to the cen-
tral and peripheral pulsatile BP components (Table S11) 
remained significant when additionally adjusted for diastolic 
BP (P≤0.001). Significance weakened when these hazard 
ratios were further adjusted for MAP (0.026≤P≤0.32) in-
stead of diastolic BP. Sensitivity analyses of the primary 
end point in relation to central and peripheral pulsatile BP 
components in various subgroups (Table S12) delineated 
by treatment status, history of cardiovascular disease, or 
the presence of renal dysfunction at baseline confirmed the 
results reported in Table 3.
Discussion
The key point addressed by our study was whether the cen-
tral pulsatile BP components, as exemplified by systolic BP or 
PP, provide statistically and clinically relevant improvement 
in risk stratification over and beyond their counterparts meas-
ured peripherally. The risk of the composite cardiovascular 
end point, total mortality, a coronary end point, and stroke 
increased with higher pulsatile BP, irrespective of whether 
pulsatile BP was measured centrally or peripherally. The 
strength of these associations was similar for central com-
pared with peripheral pulsatile BP. The correlations close to 
unity (P≥0.95) between the central and peripheral pulsatile 
BP levels provided the explanation (Table 2). The under-
lying physiological explanation is that the radial pulse wave 
is recorded and calibrated on brachial BP, whereas the central 
waveform, from which central systolic BP and PP are derived, 
is extrapolated using a transfer function.8 Recalibration of the 
radial pulse wave on diastolic BP and MAP to reconstruct the 
aortic pulse wave did not weaken these correlations (Table 
S13). Adjustment of the central pulsatile BP for its peripheral 
counterpart and vice versa removed the significance of both 
central and peripheral pulsatile BP with gradients in the 5-year 
risks conferred across the BP scales (Figure 2). Furthermore, 
diastolic BP was similar centrally and peripherally (Table 1), 
and women had a higher heart rate and higher central and pe-
ripheral PP than men had (Table S7). These observations are 
in keeping with long-established hemodynamic principles13 
and represent an internal validation of our study results.
Our current findings must be placed within the context 
of the abundant literature, suggesting that the association of 
adverse health outcomes with central systolic BP and central 
PP must be closer than with their peripheral counterparts. 
However, approximately half of the published studies had 
a cross-sectional design with preclinical outcomes.14-19 The 
longitudinal studies related a broad spectrum of outcomes 
with central BP, but applied different technologies to quan-
tify the risk marker and not always accounted for peripheral 
BP.16,17,20-25 Other factors limiting the interpretation of the 
available literature are a sample size of <200,14,15,26,27 a fol-
low-up confined to 1 year or less,20 selective enrollment of 
patients with hypertension,14,19,22,26,28, renal dysfunction15,18,29 
or coronary heart disease.20 In a meta-analysis of summary 
statistics extracted from 11 studies that included 5648 
patients followed up for 3.8 years, central PP was only as-
sociated with a marginally higher relative risk of clinical 
end points (P=0.057).30 Most patients were either elderly 
or had coronary arterial or end-stage renal disease.30 In the 
Conduit Artery Function Evaluation Study,22 the multivari-
able-adjusted hazard ratios relating peripheral and central 
PP to the composite cardiovascular end point were similar 
(1.10 [P=0.050] versus 1.11 [P=0.048]), again confirming 
our current findings, but in the setting of a randomized con-
trolled trial.
Strengths and Limitations
From the perspective of generalizability, participants were 
enrolled in 9 countries and 3 continents. End points encom-
passed both fatal and nonfatal events, which were all vali-
dated against the source documents available in each country. 
Notwithstanding these strengths, our study has limitations. 
Table 4. Fit of Cox Models Relating the Primary End point to Central and 
Peripheral Pulsatile Blood Pressure Components
Models −2 Log L χ2 Statistic P Value R2 (%)*
Base model† 3661.5    
  +cSBP 3621.4 40.1 <0.001 0.713
  +cPP 3641.0 20.5 <0.001 0.365
  +pSBP 3620.0 41.5 <0.001 0.737
  +pPP 3640.7 20.9 <0.001 0.371
Base model including pSBP‡ 3620.0    
  +cSBP 3620.0 0.004 0.95 <0.001
Base model including pPP‡ 3640.7    
  +cPP 3640.5 0.18 0.67 0.003
Base model including cSBP§ 3621.4    
  +pSBP 3620.0 1.35 0.24 0.024
Base model including cPP§ 3641.0    
  +pPP 3640.5 0.52 0.47 0.009
cPP indicates central pulse pressure; cSBP, central systolic BP; HDL, high-
density lipoprotein; pPP, peripheral pulse pressure; and pSBP, peripheral 
systolic BP.
*R2 is an estimate of the additional variance explained (https://apha.confex.
com/apha/134am/techprogram/paper_135906.htm).
†Included cohort (random effect), sex, and baseline characteristics including 
age, body mass index, smoking and drinking, total-to-HDL cholesterol ratio, 
estimated glomerular filtration rate, antihypertensive drug intake, history of 
cardiovascular disease, and diabetes mellitus.
‡Base model, including pSBP or pPP, respectively, extended by cSBP or cPP.
§Base model, including cSBP or cPP, respectively, extended by pSBP or pPP.
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First, we had no information on blacks of African descent or 
blacks born and living in Africa, who are more susceptible to 
the complications of hypertension than other ethnic groups. 
Second, the tonometric reconstruction of the aortic pulse 
wave from the radial pulse wave requires the application of 
a generalized transfer function, which has been criticized.31 
However, the tonometric approach, as applied in our current 
study, has been invasively validated.8 Third, the tonometric 
method requires a 2-point calibration, either on peripheral 
systolic and diastolic BP or on peripheral diastolic BP and 
MAP. Whatever calibration was applied, the correlations be-
tween the central and peripheral systolic BP components were 
equally high (Table 2 and Table S13). In calculating peripheral 
MAP from systolic and diastolic BP, a form factor of 33 or 40 
can be applied.32 Whether MAP is computed using form factor 
33 or 40 does not matter in Cox regression (data not shown). 
Indeed, the difference in calibration on MAP form factor 33 
versus 40 involves a constant factor in each individual partic-
ipant, that is, 7% of PP. This constant will not affect the sig-
nificance of hazard ratios; if expressed per 1-SD increment in 
the pulsatile BP, hazard ratios will also be similar. Fourth, the 
rates of coronary revascularization, a component of the pri-
mary and coronary end points differed across cohorts, based 
on sample size and the age distribution: 2.31% (N=27/1171) 
in Noordkempen, Belgium; 0.05% (N=1/1823) in JingNing, 
China; 2.75 (N=35/1271) in Buenos Aires, Argentina; and 
2.30% (N=10/435) in Finland. However, analyses were 
adjusted for cohort as a random effect. Finally, confound-
ing factors, such as antihypertensive treatment, smoking and 
drinking status, or renal dysfunction, were only assessed at 
baseline so that they could not be accounted for in a time-
dependent manner.
Perspectives
In a large population-based cohort, the strength of the associa-
tions of the primary and secondary end points with the central 
BP components was not stronger than with their peripheral 
counterparts. Thus, the concept that central systolic BP and 
central PP would refine risk stratification over and beyond pe-
ripheral systolic BP or peripheral PP could not be confirmed. 
In other words, a carefully recorded peripheral systolic BP or 
PP is accurate in risk stratification without need of measuring 
their central counterparts in adults aged ≥30 years. Our current 
analysis is relevant for clinical medicine but has no bearing on 
the key role of studying central hemodynamic measurements 
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Figure 2. Heat maps depicting the 5-year risk 
of the primary end point in relation to central 
and peripheral systolic blood pressure (SBP) or 
pulse pressure (PP) in 5608 study participants. 
Heat maps were derived by Cox proportional 
hazard regression. Risk estimates were 
standardized to the average of the distributions 
in the whole study population (mean or ratio) 
of cohort identifier, sex, age, body mass index, 
smoking and drinking, the total-to-HDL (high-
density lipoprotein) serum cholesterol ratio, the 
estimated glomerular filtration rate, intake of 
antihypertensive drug, history of cardiovascular 
disease, and diabetes mellitus. Numbers 
in grids A and C represent the percent of 
participants within each cross-classification 
category of central and peripheral SBP or PP. 
Numbers in grids B and D represent the 5-year 
risk of a primary end point.
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What Is New?
•	 In a population-based cohort of people aged ≥30 years, the risk of a 
composite cardiovascular end point, total mortality, a coronary end point 
and stroke increased with higher systolic blood pressure and pulse pres-
sure, irrespective of whether these pulsatile blood pressure components 
were measured centrally or peripherally. Our study showed that central 
systolic blood pressure and pulse pressure did not improve risk stratifi-
cation over and beyond their peripheral counterparts.
•	Correlations close to unity between the central and peripheral pulsatile 
blood pressure levels provided the explanation.
What Is Relevant?
•	A carefully recorded peripheral pulsatile blood pressure component 
is sufficient in risk stratification without the need of measuring their 
central counterparts to refine risk prediction in adults older than 30 
years.
•	Our observations are relevant for clinical medicine, but have no bearing 
on the key role of studying central hemodynamic measurements as a 
way to gain deeper insight in the pathophysiology of cardiovascular 
disease.
Summary
Associations of cardiovascular complications with systolic blood 
pressure and pulse pressure were not stronger if blood pressure 
was measured centrally, compared with peripherally. The empha-
sis in daily clinical practice should remain on the careful measure-
ment of brachial blood pressure.
Novelty and Significance
